Aytu BioScience (NASDAQ:AYTU) has received
confirmation from the FDA to begin distribution of its COVID-2019
IgG/IgM Rapid Test throughout the U.S. The test is intended for
professional use and delivers results between 2 and 10 minutes at the
point-of-care.
The company expects delivery of its first shipment of 100,000 tests this week.
This point-of-care test has been validated in a 126 patient clinical trial and is CE marked.
Shares are up 14% premarket.
https://seekingalpha.com/news/3554152-aytu-bio-to-distribute-covidminus-19-igg-igm-rapid-test-shares-up-15-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.